Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
Authors: Ragavan, Meera V | Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer | September 10, 2024 | PubMed abstract
